Search Results for “diagnostic” – Page 16 – media

Prostate Cancer Blood Test Found Equally Effective Across Ethnic Groups

Stockholm3, a prostate cancer test that analyzes a combination of protein and genetic markers from a blood sample using an algorithm, has been shown to predict the likelihood of clinically significant cancer with greater accuracy than the conventional prostate-specific antigen (PSA) test. Research involving over 90,000 men indicates that Stockholm3 outperforms PSA, helping to avoid unnecessary MRIs and biopsies, and identifying serious cancers even in men with low or normal PSA levels. Historically, these studies primarily involved a predominantly White Scandinavian population, casting doubt on their applicability globally. Now, a new study has confirmed that Stockholm3 is equally effective across diverse ethnic backgrounds and continues to outperform the PSA standard significantly. The study, conducted by researchers at Karolinska Institutet (Stockholm, Sweden) where the Stockholm3 blood test was developed, involved more than 2,000 men from 17 clinics, with ethnic backgrounds including 16% Asian, 24% African-American, 14% Latin American, and 46% White ...
- Source: drugdu
- 69
- August 9, 2024
MRC and MND Association award £3.9m to KCL and UCL for ALS/FTD research

The Medical Research Council and the Motor Neurone Disease (MND) Association have awarded researchers from King’s College London (KCL) and University College London (UCL) £3.9m to investigate an early disease pathology in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The team aims to explore and systematically investigate the axonal dysfunction in neurodegeneration and design therapeutic strategies to address the disease at an early stage. Axonal dysfunction occurs when there is a complete degeneration of axons – parts of the neurons that allow them to carry signals and transmit information to other cells. These results are seen in neurodegenerative diseases such as ALS and FTD. ALS is a fatal type of MND that causes progressive degeneration of nerve cells in the spinal cord and brain, while FTD is the result of damage to neurons in the frontal and temporal lobes of the brain. Combined, these conditions are estimated to affect ...
- Source: drugdu
- 75
- August 9, 2024
【EXPERT Q&A】FDA Approves new colorectal cancer Screening method, How will it be implemented?

Drugdu.com expert’s response: The Food and Drug Administration (FDA) in the United States has approved a novel screening method for colorectal cancer (CRC) known as Shield Blood Test, with the following specific implementation details: Ⅰ. Target Population The Shield Blood Test is approved for use in screening the average-risk population aged 45 or older for colorectal cancer. This is based on the high incidence of CRC within this age range and the importance of screening for early detection and treatment. Ⅱ. Detection Principle The Shield Blood Test is a qualitative in vitro diagnostic test designed to detect CRC-derived mutations in cell-free DNA (cfDNA) collected from blood samples using the Guardant Blood Collection Kit. This test assesses an individual’s risk of developing cancer by identifying specific biomarkers associated with CRC in the blood. III. Testing Process Sample Collection: Blood samples are collected from patients by physicians or other healthcare professionals using ...
- Source: drugdu
- 66
- August 9, 2024
Highly Accurate Blood Test Detects Pancreatic Cancer Early in At-Risk Patients

Pancreatic ductal adenocarcinoma (PDAC), the most prevalent type of pancreatic cancer, is highly lethal but can potentially be cured with surgery and modern treatments. There is a pressing need for a simple, quick, and accessible blood test to diagnose pancreatic cancer early in at-risk individuals. Now, a new pancreatic cancer detection test offers significantly improved accuracy, fulfilling this need and potentially boosting survival rates for these patients. Immunovia AB (Lund, Sweden) has reported enhanced outcomes for its next-generation test aimed at detecting early-stage PDAC in high-risk individuals. In April 2024, the company shared positive outcomes from the preliminary model-development study of its innovative pancreatic cancer detection test. This study incorporated 624 patient samples collected from 13 distinct clinical sites, including 129 samples from patients diagnosed with stage 1 or 2 PDAC and 495 control samples, primarily from individuals at elevated risk for hereditary and/or familial pancreatic cancer. The control group ...
- Source: drugdu
- 63
- August 8, 2024
Novel Cervical Cancer Screening Method to Reduce Need for Invasive Procedures

Cervical cancer remains a significant global health issue, with about 500,000 new cases identified annually. The incidence of cervical intraepithelial neoplasia (CIN), or precursor lesions to cervical cancer, is even more common, occurring 20 times as frequently. Timely detection of these conditions is crucial for effective treatment and improved patient outcomes, underscoring the importance of advancing screening techniques for CIN and cervical cancer. The primary methods currently employed are the human papillomavirus (HPV) test and cytology examination. While cytology is a longstanding method with widespread use, its sensitivity for detecting CIN is relatively low. Conversely, while HPV tests are highly sensitive, they often lack specificity since not all HPV infections lead to cervical lesions. This underscores the pressing need for more refined diagnostic approaches. Against this backdrop, researchers at Fujita Health University (Aichi, Japan) have been exploring biomarkers that could facilitate the early detection of cervical cancer. Their latest findings, ...
- Source: drugdu
- 90
- August 8, 2024
Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer

The FDA approved Servier Pharmaceuticals’ Voranigo as a treatment for two types of low-grade gliomas. The drug, which is projected to become a blockbuster product, comes from Servier’s $1.8 billion acquisition of Agios Pharmaceuticals’ oncology business. By Frank Vinluan A Servier Pharmaceuticals drug designed to penetrate the brain to hit its targets is now FDA approved for treating two rare types of brain cancer. The FDA approval announced Tuesday covers the treatment of adults and adolescents 12 and older who have Grade 2 astrocytoma or oligodendroglioma. The drug, vorasidenib, may be prescribed after surgery, as long as the cancers have mutations to the IDH1 or IDH2 enzymes the once-daily pill is designed to inhibit. The FDA said this regulatory decision marks the agency’s first for a systemic therapy for these cancers driven by either the IDH1 or IDH2 mutations. France-based Servier, which has its U.S. headquarters in Boston, will commercialize ...
- Source: drugdu
- 75
- August 8, 2024
New AI Protocol Instantaneously Detects Cancer Genomic Biomarkers Directly from Tumor Biopsy Slides

The late 90s marked the beginning of the era of precision oncology, yet recent studies in the U.S. indicate that most cancer patients are not receiving FDA-approved precision therapies. Factors such as high costs, extensive tissue requirements, and lengthy processing times have hampered the broader adoption of precision oncology, often leading to treatments that are not only suboptimal but potentially harmful. A significant barrier is the lack of testing; many cancer patients endure critical delays waiting for standard genomic tests following an initial tumor diagnosis, which can be life-threatening. Now, a groundbreaking advancement has been made with the development of a new generation of artificial intelligence (AI) tools that enable the rapid and cost-effective detection of clinically actionable genomic alterations directly from tumor biopsy slides. This innovation could cut weeks and save thousands of dollars in clinical oncology treatment workflows for diseases like breast and ovarian cancers. The new AI ...
- Source: drugdu
- 89
- August 7, 2024
Highly Accurate Blood Test Detects Pancreatic Cancer Early in At-Risk Patients

Pancreatic ductal adenocarcinoma (PDAC), the most prevalent type of pancreatic cancer, is highly lethal but can potentially be cured with surgery and modern treatments. There is a pressing need for a simple, quick, and accessible blood test to diagnose pancreatic cancer early in at-risk individuals. Now, a new pancreatic cancer detection test offers significantly improved accuracy, fulfilling this need and potentially boosting survival rates for these patients. Immunovia AB (Lund, Sweden) has reported enhanced outcomes for its next-generation test aimed at detecting early-stage PDAC in high-risk individuals. In April 2024, the company shared positive outcomes from the preliminary model-development study of its innovative pancreatic cancer detection test. This study incorporated 624 patient samples collected from 13 distinct clinical sites, including 129 samples from patients diagnosed with stage 1 or 2 PDAC and 495 control samples, primarily from individuals at elevated risk for hereditary and/or familial pancreatic cancer. The control group ...
- Source: drugdu
- 80
- August 7, 2024
FDA Grants Accelerated Approval to Adaptimmune Therapeutics’ Tecelra for Adults with Synovial Sarcoma Who Have Undergone Prior Chemotherapy

By Don Tracy, Associate Editor Regulatory action marks the first engineered cell therapy approved for a solid tumor cancer in the United States.The FDA has granted accelerated approval to Adaptimmune Therapeutics’ Tecelra (afamitresgene autoleucel), an engineered cell therapy that targets resectable or metastatic synovial sarcoma in adults who have undergone prior chemotherapy and are HLA-A*02 positive with MAGE-A4 antigen expression. The treatment, which was approved based on results from the SPEARHEAD-1 trial, marks the first engineered cell therapy for a solid tumor cancer to be approved in the United States, according to the company.1 “The approval of Tecelra is a momentous step in Adaptimmune’s journey to redefine the way cancer is treated and the culmination of a decade of groundbreaking R&D. I want to thank the patients, caregivers, investigators, and clinical teams as well as everyone at Adaptimmune and our partners who made possible this watershed moment for cell therapy ...
- Source: drugdu
- 97
- August 6, 2024
Artificial Intelligence Test Determines Risk of Bowel Cancer Recurrence After Surgery

Bowel cancer, commonly referred to as colorectal cancer, can develop anywhere in the large bowel, including the colon and rectum. It ranks among the most prevalent cancers globally, with 1.9 million new cases recorded in 2020. The current protocols for determining the need for chemotherapy for patients with early-stage bowel cancer are not consistently reliable. As a result, some patients receive chemotherapy unnecessarily, while others who might benefit from it do not receive it and may face cancer recurrence. This decision is particularly challenging for stage II colon cancer, where the risk of recurrence post-surgery is generally lower. Now, a new artificial intelligence (AI) test can predict the risk of recurrence in bowel cancers, potentially helping patients avoid unnecessary chemotherapy. This test employs an AI algorithm to measure the concentration of immune cells known as CD3 in tumors at the early stages of bowel cancer. Previous studies have indicated that ...
- Source: drugdu
- 67
- August 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.